← Eichor
Study identifier: NCT07243262 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)

Condition: Pancreatic Cancer · PDAC - Pancreatic Ductal Adenocarcinoma  ·  Sponsor: Imperial College London

PhaseN/A
Planned participants6079
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers. Pancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If the investigators find pancreatic cancer at a late stage, it reduces the number of treatment choices for patients. Our test could be offered to patients who are experiencing vague symptoms, which might be caused either by pancreatic cancer or a common illness. This test could help doctors to identify which of those patients may have pancreatic cancer, and ensure they get referred for specialised pancreatic cancer tests. The investigators hope that this will allow us to diagnose pancreatic cancer earlier, increasing treatment choices for patients and improving survival from pancreatic cancer. The investigators have previously conducted a study (VAPOR1) which collected breath samples from people with and without pancreatic cancer. When the investigators analysed these samples, they found that there is a difference in the volatile organic compounds breathed out by people who have pancreatic cancer compared to those that do not. The investigators used these 'markers' to develop a breath test to diagnose pancreatic cancer. …

This description comes directly from the study's public registry record.

Talk to the study team

Emma Austin  ·  +44 (0)20 7594 3653  ·  vapor@imperial.ac.uk

Caoimhe Walsh, MBBS, MRCS  ·  +44 (0)20 7594 3653  ·  vapor@imperial.ac.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Imperial College Healthcare NHS TrustLondon, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07243262